Clinical Trial Update: Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 2 results for Brentuximab vedotin (SGN-35) in transplant-eligible patients with relapsed or refractory Hodgkin lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-10-21